Track record · closed signal

Pediatrix Medical Group, Inc. (MD) — closed signal from November 3, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on February 1, 2026.

Predicted vs. what happened

MD price · publication thesis → realized outcomesplit-adjusted
$19.61 Published $23.54 Target $21.00 Window close $24.99 Peak
$19.00 – $19.80Entry zone — fair-value band
$19.61Published — price the day we called it
$23.54Target — the price the thesis aimed for
$24.99Peak — highest point inside the window, not a realized return
$21.00Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 17 days.

Peak price
$24.99
peak on November 28, 2025 — not a realized return
Peak gain
+27.4%
peak, from the publication price
Window close
$21.00
end-of-window price, context only
Days to target
17
Window
November 3, 2025 – February 1, 2026

The thesis — published November 3, 2025

Predicted growth
+20%
over the measurement window
Target price
$23.54
the price the thesis aimed for
Entry zone
$19.00 – $19.80
the fair-value band we waited for
Price at publication
$19.61
published November 3, 2025
Confidence
62%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Pediatrix reported better-than-expected Q3 results and raised its outlook, easing earlier worries. Price behavior suggests buyers are returning and momentum is improving, with lots more people buying than usual. A simple plan is to start near the lower end of the recent range and add only if the price pushes above 20.20. Still, who pays the bills and how well the team executes can sway profits, so keep positions modest while the turnaround takes shape.

Primary drivers

  • Stronger Q3 results and higher guidance lifted expectations for the year
  • Buying interest and momentum appear to be improving with rising activity
  • Healthcare services rebound story could support a multi-quarter recovery
  • Key risks: execution missteps and a tougher payer mix could pressure results

How it played out

MD: target reached in 17 days

Lyra published MD at 19.61 on 2025-11-03, with expected growth of 20% over the short-term window. The thesis pointed to stronger Q3 results, higher guidance, improving buying interest, and a possible healthcare services rebound. It also flagged execution missteps and a tougher payer mix as risks.

Inside the window from 2025-11-03 to 2026-02-01, MD rose to a peak of 24.99 on 2025-11-28. That was above the 23.54 target, with a 27.4% peak gain. The target was reached in 17 days. The stock ended at 21. The thesis played out.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MD signals